Synonym
FHD-286; FHD 286; FHD286;
IUPAC/Chemical Name
N-((S)-1-((4-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)thiazol-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide
InChi Key
JBLQNFBXKOAIHG-FCEWJHQRSA-N
InChi Code
InChI=1S/C24H30N6O6S2/c1-15-10-29(11-16(2)36-15)21-7-5-6-18(25-21)20-14-37-24(27-20)28-23(32)19(13-35-3)26-22(31)17-8-9-30(12-17)38(4,33)34/h5-9,12,14-16,19H,10-11,13H2,1-4H3,(H,26,31)(H,27,28,32)/t15-,16+,19-/m0/s1
SMILES Code
COC[C@@H](C(NC1=NC(C2=CC=CC(N3C[C@@H](O[C@@H](C3)C)C)=N2)=CS1)=O)NC(C4=CN(C=C4)S(C)(=O)=O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
562.66
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fiskus W, Piel J, Collins M, Hentemann M, Cuglievan B, Mill CP, Birdwell CE,
Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K,
Takahashi K, Hammond D, Reville PK, Wang J, Loghavi S, Sen R, Ruan X, Su X,
Flores LB, DiNardo CD, Bhalla KN. BRG1/BRM inhibitor targets AML stem cells and
exerts superior preclinical efficacy combined with BET or menin inhibitor.
Blood. 2024 May 16;143(20):2059-2072. doi: 10.1182/blood.2023022832. PMID:
38437498.
2: Redin E, Sridhar H, Zhan YA, Pereira Mello B, Zhong H, Durani V, Sabet A,
Manoj P, Linkov I, Qiu J, Koche RP, de Stanchina E, Astorkia M, Betel D,
Quintanal-Villalonga Á, Rudin CM. SMARCA4 controls state plasticity in small
cell lung cancer through regulation of neuroendocrine transcription factors and
REST splicing. J Hematol Oncol. 2024 Jul 30;17(1):58. doi:
10.1186/s13045-024-01572-3. Erratum in: J Hematol Oncol. 2024 Sep 29;17(1):89.
doi: 10.1186/s13045-024-01609-7. PMID: 39080761; PMCID: PMC11290012.
